In addition, there was little evidence to support an effect of SGLT2 inhibition on prostate-specific antigen (PSA) levels (β = −0.14, 95% CI = −0.30 to 0.03, p = 0.11; Table S6), which suggested that SGLT2 inhibition is likely to show an effect on reducing risk rather than influencing the diagnostic workup for prostate cancer. Here, SLC5A2 is linked to prostate cancer.